News

Under the terms of the agreement, Biovail has acquired the worldwide rights to develop, manufacture and market BVF-068 and BVF-247. In return, Biovail will pay an upfront fee

The first Phase I study evaluated a randomized, weight-based, single ascending dose of GlycoPEG-GCSF compared to Neulasta in 53 healthy subjects. This trial shows that single doses of

Nastech will immediately advance Teriparatide (PTH1-34) nasal spray into a Phase II clinical study to evaluate the change in bone mineral density, which the FDA has previously indicated

Strong activity was observed in the Phase I clinical trial consisting of 40 patients with advanced solid tumors. AV-951 was also found to be well tolerated. Of the

The new BCM MRSA ELF culture media will be manufactured and sold by Biosynth under license from Invitrogen’s molecular probes business. BCM MRSA ELF is designed to provide

This project is part of a contract awarded in 2005 by the US Department of Health and Human Services (HHS) for the development of a new cell culture-

The final 12-month data confirm the trends seen in the previous data at six and nine months for both smoking cessation and long-term smoking abstinence. Importantly, there was

Advanced Cell Technology (ACT) had already published 6-month data for the trial. The trial also showed evidence that the hearts of the patients that received the therapy showed

Results from the COMET (combination of Mmthotrexate and etanercept in active early rheumatoid arthritis) trial will be presented at the American College of Rheumatology (ACR) scientific meeting in